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Early Exclusion of Major Adverse Cardiac Events in Emergency Department 1 
Chest Pain Patients: a prospective observational study 2 
 3 
ABSTRACT 4 
 5 
Background The current evaluation of chest pain patients presenting to an 6 
Emergency Department (ED) with suspected acute coronary syndrome (ACS) is a 7 
lengthy process involving serial measurements of troponin.   8 
 9 
Objectives  We aimed to validate the diagnostic accuracy of a Thrombolysis in 10 
Myocardial Infarction (TIMI) score with single high-sensitive cardiac troponin T (hs-11 
cTnT) for early rule out of 30-day major adverse cardiac events (MACE), and to 12 
compare the TIMI score with combinations of heart-type fatty acid binding protein 13 
(H-FABP) and a modified HEART score. 14 
 15 
Methods  We recruited 602 consecutive adult patients with chest pain and suspected 16 
ACS in ED. Each patient had TIMI and HEART scores, and a point-of-care H-FABP 17 
test.  18 
 19 
Results  MACE occurred in 42 (7.0%) patients within 30 days. A low risk for 30-day 20 
MACE was identified by a modified TIMI score of 0 in 65 (11%) patients, and by a 21 
HEART score ≤2 in 96 (16%) patients.  No MACE occurred in these groups giving 22 
both scores a sensitivity of 100% (95%CI 91.6-100% ), and a specificity of 11.6% 23 
(95%CI 9.2-14.5%) and 17.1% (95%CI 14.2-20.5%) respectively.  Use of combined 24 
TIMI and HEART scores improved the specificity further to 22.0% (95%CI 18.7-25 
25.6%) without lowering sensitivity. Early H-FABP measurement >7g/L had a 26 
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sensitivity of 41.5% (95%CI 27.8-56.6%) and a specificity of 91.1% (95%CI 88.4-27 
93.2%) for predicting 30-day MACE. 28 
 29 
Conclusion  A modified TIMI score of 0 or a HEART score of ≤2, incorporating a 30 
single hs-cTnT level, will identify patients with low risk of 30-day MACE for early 31 
discharge within 2 hours of ED arrival.  32 
 33 
Key words: acute coronary syndrome; chest pain; diagnosis; major adverse cardiac 34 
event  35 
36 
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 37 
1 INTRODUCTION 38 
Chest pain is one of the most common complaints in patients presenting to emergency 39 
departments (ED) globally,[1,2] representing 2.5% of all ED presentations in Hong 40 
Kong.[3]  Acute coronary syndrome (ACS) cannot be immediately excluded in the 41 
majority of patients presenting with chest pain, and is confirmed in about 15-25% 42 
cases.  The current evaluation of patients in most EDs is a lengthy process that 43 
involves serial electrocardiographs (ECGs) and troponin tests taken 3-6 hours apart.[4]  44 
However, challenges over ED crowding and the need for acceptable risk stratification 45 
have prompted the search for safe, cheap, but effective accelerated chest pain 46 
pathways.[4-7] 47 
Risk stratification tools which predict a very low risk of major adverse cardiac events 48 
(MACE) may be more clinically relevant to the ED specialist than precise diagnostic 49 
labels.  In the Asia-Pacific region a 2-hour diagnostic protocol involving serial point-50 
of-care biomarkers, such as troponin I, creatine kinase MB, and myoglobin, combined 51 
with ECG changes and a Thrombolysis in Myocardial Infarction (TIMI) score has 52 
been shown to safely exclude 30-day MACE in low risk patients with chest 53 
pain.[4,5,8,9]  High-sensitivity troponin T (hs-cTnT) and troponin I (hs-cTnI) tests 54 
perform well in the early diagnosis of acute myocardial infarction (AMI), non-ST 55 
elevation myocardial infarction (NSTEMI) and in the prediction of two year 56 
mortality.[10-12]   57 
Despite evidence favoring early rule out pathways, there is still a need for further 58 
validation and refinement of such tools using different diagnostic pathways, in other 59 
clinical settings, evaluating other potential markers such as heart-type fatty acid 60 
binding protein (H-FABP), and with other clinical tools such as HEART score.[13-17] 61 
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H-FABP is thought to be superior to creatine kinase-MB or cardiac troponins in early 62 
detection of ischemic myocardial necrosis.[18]   63 
In this study we aimed firstly to validate an early TIMI score with hs-cTnT to rule out 64 
30-day MACE, and secondly to compare this with H-FABP, a modified HEART 65 
score and their combined use.  Applying this protocol in clinical practice has the 66 
potential to reduce ED waiting times, ED crowding and hospital admission rates for 67 
chest pain patients. This is a sub-study of a prospective observational study of adult 68 
patients with potentially cardiac chest pain who underwent computer tomography (CT) 69 
scan to evaluate the usefulness of coronary calcium score in risk-stratifying chest pain 70 
patients.    71 
 72 
2 METHODS 73 
2.1 Study design 74 
We conducted a prospective study between 4 March 2013 and 31 March 2014 in the 75 
ED of a tertiary referral university hospital in Hong Kong. The study is registered 76 
with ClinicalTrials.gov (no. NCT02364271). Ethical approval was obtained from the 77 
joint Institutional Review Board of the Chinese University of Hong Kong and Prince 78 
of Wales Hospital. Written informed consent was taken from all participants, and the 79 
study complied fully with the Declaration of Helsinki and Good Clinical Practice 80 
Guidelines.[19,20]  The ED has approximately 150,000 new patient registrations 81 
every year, with an admission rate of 34%, and average waiting times to see a doctor 82 
in the ED of over 4 hours during the busiest winter surges. Hospital bed occupancy 83 
frequently exceeds 100%.  84 
2.2 Participants 85 
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The study included consecutive eligible patients presenting to the ED from 9am to 86 
4pm from Monday to Friday.  We included patients who had chest or epigastric pain 87 
within 24 hours prior to ED presentation, and symptoms suggestive of cardiac chest 88 
pain, and for whom hs-cTnT measurement was requested by the assessing emergency 89 
physician. Patients were excluded if STEMI or ACS was confirmed immediately on 90 
ED arrival, or if there was hemodynamic instability, pregnancy, under the age of 18, 91 
or unable to obtain informed consent.  Data collection commenced at triage.   The 92 
funding for this study involved ED assessments for the role of CT calcium scoring to 93 
rule in ACS and MACE so we excluded patients  if they had a pacemaker or any 94 
metal device implantation, or if there was previous coronary artery bypass grafting 95 
(CABG) or percutaneous coronary intervention (PCI). With this exclusion criteria and 96 
the recruitment in less than 8 hours a day and in working days only, the number of 97 
subjects included is not very high.  Only one patient was lost in the 30 day telephone 98 
follow-up and was excluded from the analysis.  99 
2.3 Measurements  100 
Data collected by research staff included patient characteristics, medical history, 101 
conventional risk factors and current medication. An ECG and serial hs-cTnT 102 
(Elecsys® Troponin T hs, Roche Diagnostics, Germany, upper reference limit (99th 103 
percentile) 14ng/L) are part of the chest pain protocol in our hospital and all results 104 
were obtained from the hospital laboratory within about an hour of sampling.  The H-105 
FABP point-of-care (POCT) test (Shenzhen Kang Sheng Bao Bio-technology Co., 106 
Ltd; upper reference limit (99th percentile) 7g/L) was performed at the same time as 107 
blood was withdrawn for hs-cTnT.  The research staff obtained the hs-cTnT results 108 
from hospital central laboratory, performed the H-FABP measurement and scored the 109 
TIMI and HEART charts for  all patients. We recorded a negative response if the 110 
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patient was unsure of an answer to a question (e.g. family history of cardiac disease). 111 
Serial hs-cTnT measurements were performed when assessing physician decided it 112 
was necessary to confirm the diagnosis. Assessing physicians adjudicated the final 113 
diagnosis independently without reference to the scoring charts and the diagnosis was 114 
reviewed, also without reference to the charts, by the study investigator to ensure 115 
compliance with the Third Universal Definition of Myocardial Infarction. [22] We 116 
retrieved follow-up data, including subsequent visits to ED, hospital readmission for 117 
evaluation of chest pain and all cardiac procedures, from the hospital authority’s 118 
computerized medical system (CMS) and verified them via telephone follow-up at 30 119 
days after initial presentation. We also obtained information about death, myocardial 120 
infarction, readmission for ACS, and all cardiac testing and coronary 121 
revascularization procedures, whether in our hospital or other hospitals from the CMS 122 
and the telephone follow ups.  Research staffs collecting this data were not blinded 123 
from the ED data. 124 
2.4 Definitions 125 
MACEs include the condition at initial hospital presentation and subsequent events 126 
within 30 days, and encompass both safety and effectiveness elements. Safety 127 
outcomes consist of all-cause mortality (including cardiac death), cardiac arrest, 128 
myocardial infarction and cardiogenic shock. Effectiveness outcomes consist of 129 
revascularization (e.g. coronary artery bypass grafting or percutaneous coronary 130 
intervention), ventricular arrhythmia needing intervention and high-degree 131 
atrioventricular block needing intervention.[21]  132 
Myocardial infarction was defined according to global taskforce recommendations 133 
requiring evidence of myocardial necrosis and ischemia.[22-Error! Reference 134 
source not found.] Evidence of myocardial ischemia includes chest pain, or ECG 135 
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changes or echocardiographic evidence of new loss of viable myocardium or new 136 
regional wall motion abnormality. Necrosis was diagnosed on the basis of either 137 
a >100% change in the concentration of cardiac troponin in subsequent serial 138 
laboratory tests or an increase to >14ng/L in a subsequent serial troponin test while 139 
the concentration of the first test is <14ng/L and the patient has a glomerular filtration 140 
rate of ≥60ml/min with no history of cardiac failure.  If no clear alternative cause of 141 
the troponin rise is apparent, and if the clinical presentation was suggestive of acute 142 
coronary syndromes, an adjudicated diagnosis of MI was made. MI consists of 143 
NSTEMI and ST elevation MI (STEMI).[22-Error! Reference source not found.] 144 
2.5 TIMI and modified HEART Scores 145 
We considered a TIMI score of 0 as low risk for 30-day MACE.  We defined a 146 
negative initial hs-cTnT result as a concentration of ≤14ng/L. We considered a 147 
modified HEART score ≤2 as low risk for 30-day MACE. Modified from the original 148 
HEART score, only the presence of ST-deviation of >0.05mV was considered in the 149 
initial ECG result which scored one point. We used initial measurement of hs-cTnT as 150 
the biomarker in the score.  151 
2.6 Primary Outcome 152 
The primary outcome was the number of patients with one or more MACE within 30 153 
days of initial ED presentation, including the diagnosis of initial ED presentation.  154 
2.7 Statistical analysis 155 
We showed baseline characteristics of the study population as conventional 156 
descriptive statistics. Median and interquartile range are reported (IQR). We used 157 
appropriate Chi-square, Fisher’s exact, and Cochrane-Armitate test for trend for 158 
comparison of characteristics with MACE. We set statistical significance at P<0.05. 159 
We calculated sensitivity, specificity, and positive and negative predictive values 160 
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from two-by-two tables using SPSS (version 20.0.0, New York, United States) and 161 
WINPEPI (version 11.43).[Error! Reference source not found.] We did not perform 162 
an a priori sample size calculation. 163 
 164 
3 RESULTS 165 
We enrolled 604 consenting eligible patients, of whom 602 had complete test scores 166 
and 30-day follow-up.  Figure 1 shows the patient recruitment, derived level of risk, 167 
and the relationships between risk, admission and 30-day MACE. Of the 123 (20.4%, 168 
95%CI:17.3-23.8%) patients identified as having low risk of a MACE occurring 169 
within 30 days by either TIMI=0 or mHEART≤2, none had an event during the 30 170 
day follow-up period.    171 
Table 1 shows the baseline characteristics of all patients with and without 30-172 
day MACE.  A MACE occurred in 42 (7.0%, 95%CI: 5.1% to 9.2%) patients.  173 
16 (2.7% 95%CI:1.6-4.2%) patients had NSTEMI and 11 (1.8% 95%CI:1.0-174 
3.2%) had STEMI. 26 (4.3% 95%CI:2.8-6.3%) patients had emergency 175 
revascularization. 5 (0.8% 95%CI:0.3-1.9%) deaths were recorded. 176 
Table 2 shows the predictive accuracy of the TIMI and HEART scores, initial 177 
hs-cTnT test and initial ECG, and H-FABP for the prediction of MACE within 30 178 
days. A negative ECG result alone gave 23 false negative results.  This reduced to 3 179 
with the addition of hs-cTnT, and further reduced to zero false negatives when TIMI 180 
or the modified HEART scores were used. Initial H-FABP concentration ≤7g/L 181 
alone resulted in 24 false negative cases when used as a rule-out tool. In data not 182 
shown, addition of H-FABP to TIMI or HEART score did not improve the 183 
performance of the scores.   184 
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Combining TIMI>0 and mHEART>2 identified 479 (80%, 95% CI 76-83%) 185 
patients to be high risk and suggested longer observation while 498 (83%, 95%CI 79-186 
86%) patients in the current setting had a second hs-cTnT measurement.  187 
 188 
4 DISCUSSION 189 
The purpose of our study was to evaluate various combinations of risk-assessment 190 
tools for the early and safe discharge of patients.  There is no recommended 191 
sensitivity level which has universal acceptance for acceptable safety in this context, 192 
although it is appreciated that no test or protocol can achieve absolute safety.  We 193 
have set a point sensitivity of >99% as an essential parameter for selecting an 194 
appropriate rule-out tool.  Once this level is achieved then we have aimed for optimal 195 
specificity thus allowing a maximum number of patients for safe early discharge.  196 
Having set these criteria, we evaluated eight different combinations (see Table 2).  Of 197 
these combinations, only TIMI, HEART and combined TIMI/HEART achieved a 198 
sensitivity >99%.  The combined tool would allow the safe early discharge of 35 199 
patients who were admitted under the current chest pain protocol of our hospital, 200 
6.3% of the 560 patients with no evidence of 30-day MACE, a relative increase of 201 
75% compared with TIMI alone, and a 46% increase compared with using HEART 202 
alone. Specificity of the combined tool increased as compared with TIMI or 203 
mHEART scores alone and the improvement was more prominent for TIMI score 204 
with no overlap in 95% confidence interval. We also examined the c-statistics of 205 
various combination of TIMI and HEART score and their components and found that 206 
TIMI and HEART scores together achieved higher c-statistics than the individual tests 207 
alone. [26] Whether this potential benefit is worthwhile is debatable as the staff time 208 
saved by early discharge of these patients must be weighed up against the fact that all 209 
patients will require a system for accurate TIMI and/or HEART assessment at triage.                   210 
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This study shows that both a TIMI and modified HEART score, incorporating the 211 
initial result of hs-cTnT and ECG, identifies patients with chest pain for safe 212 
discharge within 2 hours of arrival. If both TIMI=0 and HEART≤2 are used to 213 
classify patients as low-risk, there is a further increase in specificity and with no loss 214 
in sensitivity compared with using either score alone.   A 1st hs-cTnT alone, 1st ECG 215 
alone, combined 1st hs-cTnT/ECG, and 1st H-FABP yielded high specificity, and may 216 
be useful to rule in 30-day MACE, but their sensitivity was less than 95%, and so not 217 
suitable to identify patients for early discharge. 218 
The findings in our study are similar to those in ASPECT but with important 219 
differences.[4]  The TIMI score incorporated a single hs-cTnT result, and with a cut 220 
off of 0, yielded a sensitivity of 100% for 30-day MACE and a specificity of 12%, 221 
which was similar to other studies.[4,9] Carlton  et al. had two studies on rapid rule-222 
out protocols for patients with a low risk of 30-day acute myocardial infarction. One 223 
involved the use of hs-cTnT≤14 ng/L, non-ischaemic ECG and the modified Goldman 224 
Score≤1, has a potential to allow early discharge of 40% of patients with suspected 225 
ACS with a sensitivity for identifying AMI of 98.8%. [27] The modified Goldman 226 
Score≤1 allows for a higher percentage of early discharge than our protocol, but it 227 
includes more presenting symptoms relating to the perception of pain than TIMI or 228 
HEART score and the mean age of patients in our study is 8 years older than their 229 
patient group, it may worth further study for the performance of these scores in 230 
elderly patient groups whose interpretation of pain may be less accurate. The other 231 
study also showed that, with single hs-cTnT result incorporated, TIMI score equals 0 232 
and HEART score≤2 achieved a sensitivity of 100% and 98.7%, and a specificity of 233 
35.0% and 14.1% respectively. [28] A study by Santi et al. found that a HEART score 234 
≤3 had 100% sensitivity and 43.7% specificity when used to rule-out patients for 30-235 
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day MACE. [29] The sensitivities achieved are similar to our study while the higher 236 
specificities may again be due to younger patient groups in their studies. Different 237 
from these three studies, our study included all-cause mortality, suggesting that the 238 
combination of TIMI equals 0 and HEART score≤2 is not only safe for discharge 239 
without MACE within 30 days. Adding H-FABP POCT did not improve specificity 240 
compared with hs-cTnT.   241 
4.1 Limitations 242 
This study has a number of limitations.  Firstly, modifications were made to both 243 
TIMI and HEART scores based on cut off criteria for hs-cTnT applied within our 244 
institution.  However, this is to be expected as newer markers emerge.  Secondly, this 245 
is a single centre study and patients who had stents or metal device implanted, or 246 
underwent coronary artery bypass grafting were excluded, giving a low MACE rate 247 
and wide confidence intervals in the accuracy measures. Nevertheless, these 248 
sensitivity results of TIMI=0 and HEART≤2 are very similar to the findings by 249 
Carlton et al.[28] Thirdly, the exact reason for admission is not always clear. Of the 250 
286 patients admitted to hospital who had no MACE at 30 days, the combined scores 251 
tool could have prevented 35 (12.2%, 95%CI 8.8-16.4%) admissions, and an 252 
aggregate of 143.5 bed days.  This assumes that patients were not admitted for other 253 
reasons than minimizing the risk of MACE but the fact that they were in a chest pain 254 
protocol suggests that ACS was the primary concern to the emergency physician.  255 
Fourthly, it is notable that POCT hs-cTnT is not available in our setting which delays 256 
the process and contributes to ED crowding.    257 
 258 
CONCLUSIONS 259 
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In conclusion, we have found that TIMI and a modified HEART score alone and in 260 
combination, incorporating a single initial result of hs-cTnT and ECG, may be used to 261 
safely identify patients with low risk of 30-day MACE for early discharge.  The 262 
strategy yielding the largest number of patients for safe discharge is a combined 263 
modified TIMI/HEART assessment including hs-cTnT. H- FABP provided no 264 
additional prognostic value to the scores as a rule-out tool.   265 
266 
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Article Summary 353 
 354 
Why is this topic important?  355 
Chest pain is the second commonest presenting complaint in adults attending 356 
emergency departments (ED) globally, and the current evaluation of patients in 357 
most EDs is a lengthy process that involves serial ECGs and troponin tests taken 358 
3-6 hours apart. There has been on-going research worldwide for protocols to 359 
speed up the process and to identifying patients at low risk of acute coronary 360 
syndrome and major adverse cardiac events for early discharge. 361 
 362 
What does this study attempt to show?  363 
We aimed firstly to validate an early TIMI score with hs-cTnT to rule out 30-day 364 
MACE, and secondly to compare this with H-FABP, a modified HEART score and 365 
their combined use. 366 
 367 
What are the key findings?  368 
We have found that TIMI and a modified HEART score alone and in combination, 369 
incorporating a single initial result of hs-cTnT and ECG, may be used to safely 370 
identify patients with low risk of 30-day MACE for early discharge.  The strategy 371 
yielding the largest number of patients for safe discharge is a combined modified 372 
TIMI/HEART assessment including hs-cTnT. H- FABP provided no additional 373 
prognostic value to the scores as a rule-out tool. 374 
 375 
How is patient care impacted?  376 
17 
 
More patients presenting with chest pain to EDs may be safely evaluated and 377 
discharged earlier thus reducing ED overcrowding. 378 
379 
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 380 
Figure legend 381 
 382 
Figure 1: Profile of participant recruitment and outcomes according to TIMI and 383 
mHEART score classifications. 384 
TIMI=Thrombolysis in Myocardial Infarction score. MACE=major adverse cardiac 385 
event. mHEART=modified HEART score.  ‘TIMI/mHEART’ means either TIMI or 386 
mHEART or both 387 
*The family history of cardiac disease in 36 patients was unclear and so were taken as 388 
‘no family history of cardiac disease’. 389 
